Anticoagulants Post-ASH This Panel continues where our last report left off, exploring the revolutionary use of antithrombotics and antiplatelets for use in the prevention of ischemic events during/after surgery, acute coronary syndrome, secondary prevention venous thromboembolism and secondary prevention for atrial fibrillation. learn more >>

Malignant Hematology Post-ASH This report captures the opinions of 7 North American experts in malignant hematology. They provide insight into the practice-changing ramifications of the data presented at ASH 2009, relevant to multiple myeloma, myelodysplastic syndrome, acute myelogenous leukemia, chronic myelogenous leukemia and lymphoma. learn more >>

Rheumatoid Arthritis Post-ACR Debrief This report is based on 6 interviews conducted with American and European rheumatology thought leaders following the American College of Rheumatology (ACR) 2009 meeting. The Panel highlights key learnings from the meeting, focusing on data that suggests any advantage for newer biologicals and small molecules compared to the standards of care for the treatment of rheumatoid arthritis. The Thought Leaders also provide insight into divergent activities and results pertaining to lupus, vasculitis, polymyositis and scleroderma. learn more >>

Osteoporosis Osteoporosis Thought Leader Panel #46 is our year-end wrap-up of developments in the area of non-hematologic bone disease, based on interviews with six members of our internationally recognized panel. In this edition we share their perspective on the “big news”, e.g. the status of Prolia. We also discuss topics that have received less attention as of late, including Conbriza (bazedoxifene), Enteripep (oral calcitonin) and oral PTH. learn more >>